MX368311B - Nuevos derivados de triazolopirazina y usos de los mismos. - Google Patents
Nuevos derivados de triazolopirazina y usos de los mismos.Info
- Publication number
- MX368311B MX368311B MX2016003968A MX2016003968A MX368311B MX 368311 B MX368311 B MX 368311B MX 2016003968 A MX2016003968 A MX 2016003968A MX 2016003968 A MX2016003968 A MX 2016003968A MX 368311 B MX368311 B MX 368311B
- Authority
- MX
- Mexico
- Prior art keywords
- kinase activity
- pharmaceutical composition
- hyper
- tyrosine kinase
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a un nuevo derivado de triazolopirazina o una sal del mismo farmacéuticamente aceptable, y una composición farmacéutica que contiene la misma como un ingrediente activo para prevenir o tratar el trastorno hiper proliferativo. La presente invención puede ser útil como un agente terapéutico para varios trastornos hiper proliferativos asociados con la excesiva proliferación celular y crecimiento causado por la actividad de cinasa anormal, tal como cáncer, psoriasis, artritis reumatoide, y retinopatía diabética, por inhibición eficiente de la actividad de la tirosina cinasa c-Met.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2013/008740 WO2015046653A1 (ko) | 2013-09-30 | 2013-09-30 | 신규한 트리아졸로 피라진 유도체 및 그의 용도 |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2016003968A MX2016003968A (es) | 2017-01-06 |
MX368311B true MX368311B (es) | 2019-09-27 |
Family
ID=52743772
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016003968A MX368311B (es) | 2013-09-30 | 2013-09-30 | Nuevos derivados de triazolopirazina y usos de los mismos. |
Country Status (12)
Country | Link |
---|---|
US (1) | US9403831B2 (es) |
EP (1) | EP3053923B1 (es) |
JP (1) | JP6039095B2 (es) |
CN (1) | CN104703988B (es) |
AU (1) | AU2013402175B2 (es) |
BR (1) | BR112016006444B1 (es) |
CA (1) | CA2923533C (es) |
DK (1) | DK3053923T3 (es) |
ES (1) | ES2675355T3 (es) |
MX (1) | MX368311B (es) |
RU (1) | RU2643361C2 (es) |
WO (1) | WO2015046653A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190077A1 (ar) * | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
KR20180092096A (ko) * | 2017-02-08 | 2018-08-17 | 에이비온 주식회사 | 트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법 |
CN108570053A (zh) * | 2017-03-13 | 2018-09-25 | 中国科学院上海药物研究所 | 五元并六元杂环化合物、制备方法、中间体、组合和应用 |
PE20220141A1 (es) | 2019-04-02 | 2022-01-27 | Array Biopharma Inc | Inhibidores de la proteina tirosina fosfatasa |
KR102267662B1 (ko) * | 2019-11-19 | 2021-06-22 | 한국화학연구원 | 벤즈아미드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
US11987582B2 (en) * | 2021-01-27 | 2024-05-21 | Abion Inc. | Maleate salts of triazolopyrazine derivatives, compositions, methods of use, and processes of manufacturing the same |
US11964979B2 (en) * | 2022-06-27 | 2024-04-23 | Abion Inc. | Camsylate salts of triazolopyrazine derivatives |
US20230416255A1 (en) * | 2022-06-27 | 2023-12-28 | Abion Inc. | Mesylate salts of triazolopyrazine derivatives |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2476667T3 (da) | 2003-02-26 | 2014-09-15 | Sugen Inc | Aminoheteroaryl-forbindelser som proteinkinase-inhibitorer |
JP2008510792A (ja) | 2004-08-26 | 2008-04-10 | ファイザー・インク | タンパク質チロシンキナーゼ阻害剤としてのアミノヘテロアリール化合物 |
GEP20094845B (en) | 2004-08-26 | 2009-11-25 | Pfizer | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors |
EP1871377A1 (en) * | 2005-02-25 | 2008-01-02 | Kudos Pharmaceuticals Ltd | 2,4-diamino-pyridopyrimidine derivatives and their use as mtor inhibitors |
WO2007064797A2 (en) | 2005-11-30 | 2007-06-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-met and uses thereof |
NL2000613C2 (nl) * | 2006-05-11 | 2007-11-20 | Pfizer Prod Inc | Triazoolpyrazinederivaten. |
DE102008037790A1 (de) * | 2008-08-14 | 2010-02-18 | Merck Patent Gmbh | Bicyclische Triazolderivate |
WO2011058478A1 (en) * | 2009-11-16 | 2011-05-19 | Pfizer Inc. | Substituted triazolopyrimidines as pde8 inhibitors |
PE20160588A1 (es) | 2009-12-31 | 2016-07-09 | Hutchison Medipharma Ltd | Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos |
-
2013
- 2013-09-30 BR BR112016006444-5A patent/BR112016006444B1/pt active IP Right Grant
- 2013-09-30 MX MX2016003968A patent/MX368311B/es active IP Right Grant
- 2013-09-30 RU RU2016112963A patent/RU2643361C2/ru active
- 2013-09-30 CA CA2923533A patent/CA2923533C/en active Active
- 2013-09-30 EP EP13894061.4A patent/EP3053923B1/en active Active
- 2013-09-30 DK DK13894061.4T patent/DK3053923T3/en active
- 2013-09-30 JP JP2015539492A patent/JP6039095B2/ja active Active
- 2013-09-30 CN CN201380051661.0A patent/CN104703988B/zh active Active
- 2013-09-30 AU AU2013402175A patent/AU2013402175B2/en active Active
- 2013-09-30 ES ES13894061.4T patent/ES2675355T3/es active Active
- 2013-09-30 US US14/435,974 patent/US9403831B2/en active Active
- 2013-09-30 WO PCT/KR2013/008740 patent/WO2015046653A1/ko active Application Filing
Also Published As
Publication number | Publication date |
---|---|
CN104703988B (zh) | 2017-04-12 |
CA2923533C (en) | 2019-08-06 |
ES2675355T3 (es) | 2018-07-10 |
BR112016006444A2 (pt) | 2017-08-01 |
US9403831B2 (en) | 2016-08-02 |
RU2643361C2 (ru) | 2018-02-01 |
MX2016003968A (es) | 2017-01-06 |
DK3053923T3 (en) | 2018-07-23 |
AU2013402175A1 (en) | 2016-04-28 |
CA2923533A1 (en) | 2015-04-02 |
JP2015535242A (ja) | 2015-12-10 |
EP3053923A1 (en) | 2016-08-10 |
EP3053923B1 (en) | 2018-04-11 |
WO2015046653A1 (ko) | 2015-04-02 |
CN104703988A (zh) | 2015-06-10 |
AU2013402175B2 (en) | 2017-09-07 |
JP6039095B2 (ja) | 2016-12-07 |
RU2016112963A (ru) | 2017-11-09 |
US20150259350A1 (en) | 2015-09-17 |
EP3053923A4 (en) | 2017-04-12 |
BR112016006444B1 (pt) | 2021-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX368311B (es) | Nuevos derivados de triazolopirazina y usos de los mismos. | |
PH12016500582A1 (en) | Heterocyclic compounds and uses thereof | |
PH12015501595A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
MX2015016983A (es) | Moduladores del transporte nuclear y usos de los mismos. | |
PH12015502116A1 (en) | Biaryl amide compounds as kinase inhibitors | |
PH12015501598A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
PH12015501600A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
MY188450A (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
IN2014DN09434A (es) | ||
MX2015017215A (es) | Compuestos de sulfonamida biciclicos como inhibidores de los canales de sodio. | |
MX2015012850A (es) | Inhibidores de la arginina metiltransferasa y usos de los mismos. | |
MX2014000779A (es) | Derivados de carboxamida y urea que contienen pirazol heteroaromatico sustituido como ligandos del receptor de vanilloide. | |
PH12015501596A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG10201805267UA (en) | Piperazine derivatives having multimodal activity against pain | |
EA032271B9 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
WO2014193647A3 (en) | Alkenyl compounds and methods of use | |
EP4086249A3 (en) | 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | |
AU2013208104A8 (en) | Benzhydrol-pyrazole derivatives having kinase inhibitory activity and uses thereof | |
MX2018007517A (es) | Compuestos triciclicos y composiciones como inhibidores de quinasa. | |
PH12016501733A1 (en) | Pharmaceutical composition for preventing or treating skin rash | |
MX2014014814A (es) | Composicion farmaceutica para el tratamiento de inflamacion y dolor. | |
MX2014014816A (es) | Composicion farmaceutica para tratar inflamacion y dolor. | |
PH12016500444A1 (en) | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors | |
AU2013208087A8 (en) | Tryptoline derivatives having kinase inhibitory activity and uses thereof | |
UA88315U (en) | Antibacterial composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |